

Pharmaceutical company request for oral testimony at the May 15,2020
Idaho Medicaid Pharmacy & Therapeutics Committee meeting.

Submission # _05_

Date request was received: 04/30/2020

Drug: **Ajovy**

Therapeutic Drug Class: Anti-Migraine

Pharmaceutical Company: Teva

This request for oral testimony has been reviewed.

Denied as Untimely

Submission 05

From: Maria Agapova <Maria.Agapova@tevapharm.com>

Sent: Thursday, April 30, 2020 8:53 AM

To: Eide, Tamara J. <Tamara.Eide@dhw.idaho.gov>

Subject: Request to provide testimony at the May 17th P&T Committee Meeting [External Email]

Hello Tami,

Please find attached a submission of additional clinical information in support of the Teva anti-migraine product, AJOVY (fremanezumab-vfrm). I would like to request the opportunity to present this information at the upcoming P&T committee meeting on May 15, 2020.

Should you have any questions please do not hesitate to contact me. I am grateful for the opportunity to exchange scientific content with the committee.

Thank you for your time and consideration.

Best regards,



Maria Agapova, MSc, PhD
Senior Medical Outcomes Liaison, Field Medical Affairs
Cell: 206.369.4804
Maria.Agapova@tevapharm.com www.tevapharm.com

This message is intended solely for the designated recipient(s). It may contain confidential or proprietary information and may be subject to attorney-client privilege or other confidentiality protections. If you are not a designated recipient you may not review, copy or distribute this message. If you receive this in error, please notify the sender by reply e-mail and delete this message. Thank you.